Cambridge, UK and Cambridge, Massachusetts – 1 March 2007 – Acambis plc (Acambis) (LSE: ACM) announces that its investigational single-dose vaccine against Japanese encephalitis (JE), ChimeriVax™-JE, has met and exceeded the primary immunogenicity endpoint in a pivotal Phase 3 efficacy trial.
